vs

Side-by-side financial comparison of Invesco (IVZ) and Teradyne (TER). Click either name above to swap in a different company.

Invesco is the larger business by last-quarter revenue ($1.7B vs $1.3B, roughly 1.3× Teradyne). Teradyne runs the higher net margin — 31.1% vs -58.9%, a 90.0% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (87.0% vs 6.2%). Over the past eight quarters, Teradyne's revenue compounded faster (32.6% CAGR vs 7.1%).

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.

IVZ vs TER — Head-to-Head

Bigger by revenue
IVZ
IVZ
1.3× larger
IVZ
$1.7B
$1.3B
TER
Growing faster (revenue YoY)
TER
TER
+80.8% gap
TER
87.0%
6.2%
IVZ
Higher net margin
TER
TER
90.0% more per $
TER
31.1%
-58.9%
IVZ
Faster 2-yr revenue CAGR
TER
TER
Annualised
TER
32.6%
7.1%
IVZ

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IVZ
IVZ
TER
TER
Revenue
$1.7B
$1.3B
Net Profit
$-995.9M
$398.9M
Gross Margin
60.9%
Operating Margin
-86.2%
36.9%
Net Margin
-58.9%
31.1%
Revenue YoY
6.2%
87.0%
Net Profit YoY
-575.8%
EPS (diluted)
$-2.61
$2.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVZ
IVZ
TER
TER
Q1 26
$1.3B
Q4 25
$1.7B
$1.1B
Q3 25
$1.6B
$769.2M
Q2 25
$1.5B
$651.8M
Q1 25
$1.5B
$685.7M
Q4 24
$1.6B
$752.9M
Q3 24
$1.5B
$737.3M
Q2 24
$1.5B
$729.9M
Net Profit
IVZ
IVZ
TER
TER
Q1 26
$398.9M
Q4 25
$-995.9M
$257.2M
Q3 25
$356.4M
$119.6M
Q2 25
$197.4M
$78.4M
Q1 25
$171.1M
$98.9M
Q4 24
$209.3M
$146.3M
Q3 24
$55.0M
$145.6M
Q2 24
$132.2M
$186.3M
Gross Margin
IVZ
IVZ
TER
TER
Q1 26
60.9%
Q4 25
57.2%
Q3 25
58.4%
Q2 25
57.2%
Q1 25
60.6%
Q4 24
59.4%
Q3 24
59.2%
Q2 24
58.3%
Operating Margin
IVZ
IVZ
TER
TER
Q1 26
36.9%
Q4 25
-86.2%
27.1%
Q3 25
16.5%
18.9%
Q2 25
14.1%
13.9%
Q1 25
18.1%
17.6%
Q4 24
19.6%
20.4%
Q3 24
6.6%
20.6%
Q2 24
13.9%
28.8%
Net Margin
IVZ
IVZ
TER
TER
Q1 26
31.1%
Q4 25
-58.9%
23.7%
Q3 25
21.7%
15.5%
Q2 25
13.0%
12.0%
Q1 25
11.2%
14.4%
Q4 24
13.1%
19.4%
Q3 24
3.6%
19.8%
Q2 24
8.9%
25.5%
EPS (diluted)
IVZ
IVZ
TER
TER
Q1 26
$2.53
Q4 25
$-2.61
$1.62
Q3 25
$0.66
$0.75
Q2 25
$-0.03
$0.49
Q1 25
$0.38
$0.61
Q4 24
$0.46
$0.89
Q3 24
$0.12
$0.89
Q2 24
$0.29
$1.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVZ
IVZ
TER
TER
Cash + ST InvestmentsLiquidity on hand
$1.0B
$241.9M
Total DebtLower is stronger
$1.8B
$0
Stockholders' EquityBook value
$12.2B
Total Assets
$27.1B
$4.4B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVZ
IVZ
TER
TER
Q1 26
$241.9M
Q4 25
$1.0B
$293.8M
Q3 25
$973.1M
$272.7M
Q2 25
$922.7M
$339.3M
Q1 25
$821.7M
$475.6M
Q4 24
$986.5M
$553.4M
Q3 24
$1.0B
$510.0M
Q2 24
$878.5M
$421.9M
Total Debt
IVZ
IVZ
TER
TER
Q1 26
$0
Q4 25
$1.8B
Q3 25
$1.6B
Q2 25
$1.9B
Q1 25
$964.8M
Q4 24
$890.6M
Q3 24
$890.3M
Q2 24
$890.1M
Stockholders' Equity
IVZ
IVZ
TER
TER
Q1 26
Q4 25
$12.2B
$2.8B
Q3 25
$14.0B
$2.7B
Q2 25
$13.9B
$2.8B
Q1 25
$14.7B
$2.8B
Q4 24
$14.6B
$2.8B
Q3 24
$14.8B
$2.9B
Q2 24
$14.6B
$2.7B
Total Assets
IVZ
IVZ
TER
TER
Q1 26
$4.4B
Q4 25
$27.1B
$4.2B
Q3 25
$28.4B
$4.0B
Q2 25
$28.5B
$3.8B
Q1 25
$28.1B
$3.7B
Q4 24
$27.0B
$3.7B
Q3 24
$27.5B
$3.8B
Q2 24
$27.2B
$3.6B
Debt / Equity
IVZ
IVZ
TER
TER
Q1 26
Q4 25
0.15×
Q3 25
0.12×
Q2 25
0.14×
Q1 25
0.07×
Q4 24
0.06×
Q3 24
0.06×
Q2 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVZ
IVZ
TER
TER
Operating Cash FlowLast quarter
$455.8M
$265.1M
Free Cash FlowOCF − Capex
$432.2M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
0.66×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVZ
IVZ
TER
TER
Q1 26
$265.1M
Q4 25
$455.8M
$281.6M
Q3 25
$606.2M
$49.0M
Q2 25
$547.9M
$182.1M
Q1 25
$-84.6M
$161.6M
Q4 24
$316.9M
$282.6M
Q3 24
$438.4M
$166.3M
Q2 24
$489.1M
$216.1M
Free Cash Flow
IVZ
IVZ
TER
TER
Q1 26
Q4 25
$432.2M
$218.8M
Q3 25
$586.4M
$2.4M
Q2 25
$530.4M
$131.7M
Q1 25
$-108.0M
$97.6M
Q4 24
$309.9M
$225.2M
Q3 24
$410.0M
$114.4M
Q2 24
$462.4M
$171.2M
FCF Margin
IVZ
IVZ
TER
TER
Q1 26
Q4 25
25.5%
20.2%
Q3 25
35.7%
0.3%
Q2 25
35.0%
20.2%
Q1 25
-7.1%
14.2%
Q4 24
19.5%
29.9%
Q3 24
27.1%
15.5%
Q2 24
31.2%
23.5%
Capex Intensity
IVZ
IVZ
TER
TER
Q1 26
Q4 25
1.4%
5.8%
Q3 25
1.2%
6.1%
Q2 25
1.2%
7.7%
Q1 25
1.5%
9.3%
Q4 24
0.4%
7.6%
Q3 24
1.9%
7.0%
Q2 24
1.8%
6.1%
Cash Conversion
IVZ
IVZ
TER
TER
Q1 26
0.66×
Q4 25
1.09×
Q3 25
1.70×
0.41×
Q2 25
2.78×
2.32×
Q1 25
-0.49×
1.63×
Q4 24
1.51×
1.93×
Q3 24
7.97×
1.14×
Q2 24
3.70×
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

TER
TER

Segment breakdown not available.

Related Comparisons